We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Clinical evaluation of rosuvastatin in heart transplant patients with hypercholesterolemia and therapeutic failure of other statin regimens: short-term and long-term efficacy and safety results.
- Authors
Barge-Caballero, Gonzalo; Barge-Caballero, Eduardo; Marzoa-Rivas, Raquel; Paniagua-Martín, María J.; Barrio-Rodríguez, Alfredo; Naya-Leira, Carmen; Blanco-Canosa, Paula; Grille-Cancela, Zulaika; Vázquez-Rodríguez, José Manuel; Crespo-Leiro, María G.
- Abstract
We conducted an observational study of 30 heart transplant recipients with serum low-density lipoprotein cholesterol ( LDL-c) >100 mg/dl despite previous statin therapy, who were treated with rosuvastatin 10 mg daily (5 mg in case of renal dysfunction). Serum lipids, creatine phosphokinase ( CPK), bilirubin, and hepatic enzymes were prospectively measured 2, 4, and 12 weeks after the initiation of the drug. Clinical outcomes of patients who continued on long-term rosuvastatin therapy beyond this 12-week period were reviewed in February 2015. Over the 12-week period following rosuvastatin initiation, serum levels of total cholesterol ( TC) and LDL-c and the ratio TC/high-density lipoprotein cholesterol ( HDL-c) decreased steadily ( P < 0.001). Average absolute reductions of these three parameters were -48.7 mg/dl, -46.6 mg/dl, and -0.9, respectively. Seventeen (57%) achieved a serum LDL-c < 100 mg/dl. No significant changes from baseline were observed in serum levels of triglycerides, HDL-c, hepatic enzymes, bilirubin, or CPK. Twenty-seven (90%) patients continued on long-term therapy with rosuvastatin over a median period of 3.6 years, with no further significant variation in lipid profile. The drug was suspended due to liver toxicity in 1 (3.3%) patient and due to muscle toxicity in 2 (6.7%) patients. All adverse reactions resolved rapidly after rosuvastatin withdrawal. Our study supports rosuvastatin as a reasonable alternative for heart transplant recipients with hypercholesterolemia and therapeutic failure of other statin regimens.
- Subjects
HEART transplant recipients; LOW density lipoproteins; STATINS (Cardiovascular agents); CREATINE kinase; BILIRUBIN
- Publication
Transplant International, 2015, Vol 28, Issue 9, p1034
- ISSN
0934-0874
- Publication type
Article
- DOI
10.1111/tri.12585